BRAF and melanoma: Additional genetic testing helps to select medication for individuals with specific genetic mutations, an example being melanoma patients with particular mutations in the BRAF gene developing resistance against the normally used single agent BRAF inhibitors, who display a better response with combined use of MEK inhibitors [104].